vTv Therapeutics (NASDAQ:VTVT) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

vTv Therapeutics (NASDAQ:VTVT) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.15, FiscalAI reports.

vTv Therapeutics Stock Performance

vTv Therapeutics stock traded down $2.29 during mid-day trading on Thursday, reaching $21.74. The company’s stock had a trading volume of 17,774 shares, compared to its average volume of 51,027. The company has a market capitalization of $85.63 million, a price-to-earnings ratio of -20.51 and a beta of 0.28. vTv Therapeutics has a 12 month low of $21.72 and a 12 month high of $44.00. The business’s 50 day simple moving average is $29.70 and its 200 day simple moving average is $33.36.

Analysts Set New Price Targets

VTVT has been the subject of a number of research analyst reports. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. Wall Street Zen downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Zacks Research upgraded vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. BTIG Research reaffirmed a “buy” rating and set a $57.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, October 14th. Finally, HC Wainwright decreased their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.